dr. rotow on remaining questions with brigatinib in alk nsclc
Published 4 years ago • 142 plays • Length 0:52Download video MP4
Download video MP3
Similar videos
-
1:14
dr. rotow on first-line brigatinib versus crizotinib in alk nsclc
-
1:11
dr. rotow on brigatinib safety profile in alk nsclc
-
1:02
dr. rotow on the implications of next-generation alk inhibitors in nsclc
-
1:38
dr. drilon on the safety profile of brigatinib in alk nsclc
-
4:38
alta ii: brigatinib in crizotinib-resistant alk nsclc
-
1:34
dr. pennell on the use of brigatinib in alk nsclc
-
1:32
dr. stinchcombe on remaining challenges in alk nsclc
-
6:58
alta-1l: brigatinib versus crizotinib for alk nsclc
-
3:14
the key unanswered question in lung cancer?
-
1:39
is the antibody test reliable? with leonardo seoane, md and robert hart, md
-
1:05
dr. aggarwal on emerging treatment approaches in alk nsclc
-
1:43
immuno-oncology focus: questions to be answered
-
3:17
dr. shira doron answers covid-19 questions
-
3:30
drs. fern tablin and karl jandrey discuss research into detecting cats at risk for blood clots
-
3:36
outcomes of patients with newly diagnosed crlf2-rearranged b-all
-
0:58
dr. terri febbraro on the inverse correlation between time on chemotherapy and os
-
3:35
dr. ellerin answers questions about covid-19
-
3:46
dr. ellerin answers questions about covid-19
-
3:53
dr. ellerin answers questions on covid and kids and vaccines